Skip to main content
SpringerLink
Log in

Roxithromycin

A New Molecule, a New Pharmacokinetic Profile

  • Published:
Drug Investigation Aims and scope Submit manuscript

Summary

Roxithromycin is one of the newer macrolide antibiotics, and displays a superior gastrointestinal absorption, higher plasma concentrations and a longer plasma half-life than its analogue, erythromycin, thereby permitting once- or twice-daily administration. Its tissue distribution is extensive because of its high lipid solubility, and penetration into the respiratory tract tissues is adequate and comparable to that seen with erythromycin. Roxithromycin’s intracellular penetration is superior to that of erythromycin, conferring bactericidal efficacy against intracellular pathogens such as Chlamydia and Legionella pneumophila. Roxithromycin displays nonlinear phar-macokinetics, with no appreciable accumulation and a low propensity for drug interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Acar JF, Saint-Salvi B, Blanc F. Concentration of roxithromycin in tear fluid and saliva after repeat dosing. British Journal of Clinical Practice 42(Suppl. 55): 82, 1988

    Google Scholar 

  • Bégué P, Kafetzis DA, Albin H, Safran Ch. Pharmacokinetics of roxithromycin in paediatrics. Journal of Antimicrobial Chemotherapy 20(Suppl. B): 101–106, 1987

    PubMed  Google Scholar 

  • Benhamon JP, Albin H, Chretien P, D’Enfent J. Pharmacokinetics of roxithromycin after multiple dosing to patients with alcoholic cirrhosis. Roussel Report 86-965-05, 1988

    Google Scholar 

  • Bergogne-Bérézin E. Tissue distribution of roxithromycin. Journal of Antimicrobial Chemotherapy 20(Suppl. B): 113–120, 1987

    PubMed  Google Scholar 

  • Botto H, Carney M, Chretien P, Safran C. Study of the diffusion of roxithromycin into prostatic tissue after repeat oral dosing. British Journal of Clinical Practice 42(Suppl. 55): 83, 1988

    Google Scholar 

  • Chastre J, Brun P, Fourtillan JB, Soler P, Basset G, et al. Pulmonary disposition of roxithromycin (RU 28965), a new macrolide antibiotic. Antimicrobial Agents and Chemotherapy 31: 1312–1316, 1987

    Article  PubMed  CAS  Google Scholar 

  • Croteau D, Bergeron MG, LeBel M. Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography. Antimicrobial Agents and Chemotherapy 32: 561–565, 1988

    Article  PubMed  CAS  Google Scholar 

  • Delaforge M, Sartori E, Mansuy D. Effects of roxithromycin on rat hepatic P-450 cytochromes: comparison with troleandomycin and erythromycin. British Journal of Clinical Practice 42(Suppl. 55): 67–69, 1988

    Google Scholar 

  • De Rose V, Ferrara A, Mangiarotti P, Nonis A, Bertoletti R, et al. Penetration of roxithromycin in bronchial secretions. International Journal of Clinical Pharmacology Research 8: 107–110, 1988

    PubMed  Google Scholar 

  • Fraschini F, Braga PC, Biella G, Scaglione F, Montoli C, et al. Pharmacokinetics and sputum levels of josamycin after single and multiple administrations in bronchopneumopathic patients. International Journal of Clinical Pharmacology Research 3: 203–208, 1983

    PubMed  CAS  Google Scholar 

  • Kazmierczak A, Pechinot A, Tillement JP, Barre J, Chretien P, et al. Roxithromycin pharmacokinetics compared with those of spiramycin and troleandomycin after a single oral dose. Interscience Congress on Antimicrobial Agents and Chemotherapy, Los Angeles, 1988

    Google Scholar 

  • Kees F, Grobecker H, Fourtillan JB, Tremblay D, Saint-Salvi B. Comparative pharmacokinetics of single dose roxithromycin (150mg) versus erythromycin stéarate (500mg) in healthy volunteers. British Journal of Clinical Practice 42(Suppl. 55): 51, 1988

    Google Scholar 

  • Larrey D, Funck-Brentano C, Breil P, Vitaux J, Theodore C, et al. Effects of erythromycin on hepatic drug-metabolising enzymes in humans. Biochemical Pharmacology 32: 1058–1063, 1983

    Google Scholar 

  • Lebrec D, Benhamou JP, Fourtillan JB, Tremblay D. Roxithromycin: pharmacokinetics in patients suffering from alcoholic cirrhosis. British Journal of Clinical Practice 42(Suppl. 55): 63, 1988

    Google Scholar 

  • Männistö PT, Taskinen J, Ottoila P, Solkinen A, Vuorela A, et al. Fate of single oral doses of erythromycin acistrate, erythromycin stearate and pelleted erythromycin base analysed by mass-spectrometry in plasma of healthy human volunteers. Journal of Antimicrobial Chemotherapy 21(Suppl. D): 33–43, 1988

    PubMed  Google Scholar 

  • Mattina R, Bonfiglio G, Bruno E, Gianni AB, Porcellini A. Distribution of roxithromycin in odontological tissue. International Meeting on the Present and Future of the Therapy of Infections, Punta Ala, September 9, 1988

    Google Scholar 

  • Meirovich CI, Monkrull H, Strusberg AM, Brizuela N, Forti IN. Roxithromycin levels in synovial fluid. British Journal of Clinical Practice 42(Suppl. 42): 88, 1988

    Google Scholar 

  • Nilsen OG. Comparative pharmacokinetics of macrolides. Journal of Antimicrobial Chemotherapy 20(Suppl. B): 81–88, 1987

    PubMed  CAS  Google Scholar 

  • Nilsen OG, Lenfant B, Saint-Salvi B. Pharmacocinetique de la roxithromycine après administration unique et répétée chez l’insuffisant renal. Data on file, N/87/965/05, Roussel 1988a

    Google Scholar 

  • Nilsen OG, Saint-Salvi B, Lenfant B, Manuel C. Pharmacokinetics of roxithromycin in the elderly: linearity and repeat dose studies. British Journal of Clinical Practice 42(Suppl. 55): 59–60, 1988b

    Google Scholar 

  • Puri SK., Lassman HB. Roxithromycin: a pharmacokinetic review of a macrolide. Journal of Antimicrobial Chemotherapy 20(Suppl. B): 89–100, 1987

    PubMed  CAS  Google Scholar 

  • Tremblay D, Jaeger H, Fourtillan JB, Manuel C. Pharmacokinetics of three single doses ( 150, 300, 450mg) of roxithromycin in young volunteers. British Journal of Clinical Practice 42(Suppl. 55): 49–50, 1988a

    Google Scholar 

  • Tremblay D, Mignot A, Couraud L, Saux MC, Manuel C. Concentrations of roxithromycin in lung tissue after repeat dosing. British Journal of Clinical Practice 42(Suppl. 55): 73, 1988b

    Google Scholar 

  • Tremblay D, Verger C, Saint-Salvi B, Robinet D, Manuel C. Pharmacokinetics of roxithromycin in chronic renal insufficiency. British Journal of Clinical Practice 42(Suppl. 55): 61, 1988c

    Google Scholar 

  • Wollmer P, Rhodes CG, Pike VW. Measurement of pulmonary erythromycin concentrations in patients with lobar pneumoniae by means of positron tomography. Lancet 2: 1361–1363, 1982

    Article  PubMed  CAS  Google Scholar 

  • Zini R, Fournet MP, Barre J, Tremblay D, Tillement JP. In vitro study of roxithromycin binding to serum proteins and erythrocytes in humans. British Journal of Clinical Practice 42(Suppl. 55): 54, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Toxicology, Faculty of Medicine, University of Trondheim, Trondheim, Norway

    O. G. Nilsen (Faculty of Medicine)

Authors
  1. O. G. Nilsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nilsen, O.G. Roxithromycin. Drug Invest 3 (Suppl 3), 28–32 (1991). https://doi.org/10.1007/BF03258332

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03258332

Keywords

Search

Navigation